Johnson & Johnson/$JNJ
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
- Ticker
- $JNJ
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 138,200
- Headquarters
- New Brunswick, United States
- Website
- www.jnj.com
JNJ Metrics
BasicAdvanced
$652B
41.16
$6.58
0.21
$5.28
1.98%
Price and volume
Market cap
$652B
Beta
0.21
52-week high
$281.07
52-week low
$184.66
Average daily volume
7.5M
Dividend rate
$5.28
Financial strength
Current ratio
1.016
Quick ratio
0.653
Long term debt to equity
0.439
Total debt to equity
0.577
Dividend payout ratio (TTM)
79.01%
Interest coverage (TTM)
26.84%
Profitability
EBITDA (TTM)
34,150
Gross margin (TTM)
67.77%
Net profit margin (TTM)
16.20%
Operating margin (TTM)
26.59%
Effective tax rate (TTM)
9.26%
Revenue per employee (TTM)
$720,000
Management effectiveness
Return on assets (TTM)
8.46%
Return on equity (TTM)
20.02%
Valuation
Price to earnings (TTM)
41.163
Price to revenue (TTM)
6.612
Price to book
7.68
Price to tangible book (TTM)
-47.98
Price to free cash flow (TTM)
32.302
Free cash flow yield (TTM)
3.10%
Free cash flow per share (TTM)
8.391
Dividend yield (TTM)
1.95%
Forward dividend yield
1.98%
Growth
Revenue change (TTM)
7.80%
Earnings per share change (TTM)
-36.36%
3-year revenue growth (CAGR)
5.87%
10-year revenue growth (CAGR)
3.33%
3-year earnings per share growth (CAGR)
-20.75%
10-year earnings per share growth (CAGR)
1.46%
3-year dividend per share growth (CAGR)
4.40%
10-year dividend per share growth (CAGR)
5.47%
What the Analysts think about JNJ
Analyst ratings (Buy, Hold, Sell) for Johnson & Johnson stock.
Analyst projections of the future price of Johnson & Johnson stock.
Bulls say / Bears say
Q3 operational sales grew 6.0%, and J&J raised its 2026 sales and adjusted EPS outlook. That points to solid momentum across the business. (Johnson & Johnson)
TREMFYA sales rose 68% and Innovative Medicine grew 7.9%, with oncology and neuroscience products also contributing. This growth shows newer brands are helping to replace lost sales from older medicines. (CNBC, Johnson & Johnson)
In a small early-line study, half of the 20 patients treated with CARVYKTI remained alive without disease progression for five years after a single infusion, without maintenance therapy. If confirmed in broader use, this durability could strengthen J&J’s multiple-myeloma franchise. (Johnson & Johnson)
STELARA sales fell 54% in Q3 and reduced Innovative Medicine growth by about 690 basis points; other mature medicines also faced competitive pressure. Continued erosion leaves newer products with a large task to replace lost revenue. (Johnson & Johnson)
MedTech grew only 2.5% in Q3, with international sales essentially flat. Abiomed’s heart-pump sales remained slow after a UK study raised questions about use in some high-risk procedures, while regional conflict and budget pressures weighed on demand. (CNBC)
Data summarised monthly by Lightyear AI. Last updated on 22 Oct 2026.
JNJ Financial Performance
Revenues and expenses
JNJ Earnings Performance
Company profitability
Upcoming events
JNJ News
AllArticlesVideos
Funds containing JNJ
AllUSDEURGBP
Fund name | Fund size | $JNJ weighting |
|---|---|---|
Invesco Health Care S&P US Select Sector£XLVP | $552M | 10.60% |
Invesco Health Care S&P US Select Sector$XLVS | $552M | 10.60% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 9.96% |
SPDR MSCI World Health Care$WHEA | $708M | 7.30% |
SPDR MSCI World Health Care£HEAW | $708M | 7.30% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.